NCT04411693 - Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions

Diabetic Macular Edema

Interventions

DRUG

Dexamethasone implant

A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.

DRUG

Aflibercept

A single dose, 2mg, drug administered by intravitreal injection.

Trial Locations (1)

Retina Consultants of Houston, Houston